Monza

• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting
  2023-509810-13-00 4 2023-05-13 Acute Lymphoblastic Leukemia (ALL)
• OLE study in participants with pulmonary arterial hypertension Recruiting
  2023-505539-11-00 10 2023-04-06 Pulmonary Arterial Hypertension
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• A Long-term Follow-up Study of Sotatercept for PAH Treatment Recruiting
  2023-509138-21-00 5 2021-08-26 Pulmonary Arterial Hypertension (PAH)
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• Ph 3a, linerixibat, Long term safety and tolerability study in pts with PBC Recruiting
  2023-503465-33-00 5 2020-07-03 Cholestasis
• Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting
  2023-504694-20-00 9 2017-01-13 pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukem
• A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipien … Recruiting
  2025-521074-34-00 4 2026-05-15 Allogeneic peripheral hematopoietic stem cell transplant
• A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting
  2023-509628-16-00 5 2026-05-07 Small Cell Lung Cancer (SCLC)
• A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit … Recruiting
  2024-520101-39-00 5 2026-04-01 TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
• A Study of Evorpacept (ALX148) in Patients with Metastatic HER2-Positive Breast Cancer Recruiting
  2025-522012-16-00 4 2026-03-13 Breast Cancer
• Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting
  2024-519444-33-00 5 2026-03-12 HER2-expressing endometrial cancer (IHC 3+/2+)
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• A Phase 2, Randomized, Open-Label Study Of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host … Recruiting
  2025-521849-25-00 4 2026-02-17 Chronic Graft-Versus-Host Disease
• "SAFE DISCONTINUATION OF ANTIDEPRESSANTS IN INDIVIDUALS WITH CLINICALLY REMITTED DEPRESSIVE DISORDERS" Recruiting
  2023-509377-23-00 6 2026-02-13 Patients with currently remitted depressive disorders.
• A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting
  2024-516966-12-00 4 2026-02-13 Alzheimer’s disease
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad … Recruiting
  2025-521124-29-00 10 2026-02-13 Non-Small Cell Lung Cancer
• Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc … Recruiting
  2024-515765-34-00 5 2026-02-04 English First-line extensive-stage small-cell lung cancer (ES-SCLC)
• A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear … Recruiting
  2023-505661-89-00 4 2025-12-19 Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
• A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer Recruiting
  2025-521003-52-00 9 2025-12-19 HER2 Expressing Advanced Breast Cancer
• An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489 Recruiting
  2025-521155-23-00 4 2025-12-19 Pulmonary Arterial Hypertension
• A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia Recruiting
  2025-521692-31-00 5 2025-12-19 Chronic Primary Immune Thrombocytopenia

Showing 73–96 of 362 trials